EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting Liver Xor by GalNAc-siRNA Is an Effective Strategy for Hyperuricemia Therapy

Huiyan Sun, Xinxia Wang, Yongqiang Li, Yingzhi Shen, Lin Zhang, Yingjie Xu iD, Junling Liu, Xuemei Fan

Pharmaceutics · 14.07.2024 · 16 (7) · 938

DOI: 10.3390/pharmaceutics16070938 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 14.07.2024. Verfasst von Huiyan Sun und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Cell Biology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key R&D Program of China, Innovative Research Team of High-level Local Universities in Shanghai.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hyperuricemia, i.e., increased plasma uric acid concentration, is a common problem in clinical practice, leading to gout or nephrolithiasis, and is associated with other disorders, such as metabolic syndrome, cardiovascular disease, and chronic renal disease. Xanthine oxidoreductase (XOR) is a critical rate-limiting enzyme involved in uric acid synthesis and a promising target for hyperuricemia therapy. However, XOR inhibitors currently face clinical problems such as a short half-life and side effects. Here, we found that specifically targeting liver Xor with GalNAc-siRNAs had a good therapeutic effect on hyperuricemia. First, siRNAs were designed to target various sites in the homologous region between Homo sapiens and Mus musculus Xor mRNA and were screened in primary mouse hepatocytes. Then, the siRNAs were modified to increase their stability in vivo and conjugated with GalNAc for liver-specific delivery. The effects of GalNAc-siRNAs were evaluated in three hyperuricemia mouse models, including potassium oxonate and hypoxanthine administration in WT and humanized XDH mice and Uox knockout mice. Febuxostat, a specific XOR inhibitor used for hyperuricemia treatment, was used as a positive control. Targeting liver Xor with GalNAc-siRNAs by subcutaneous administration reduced plasma uric acid levels, uric acid accumulation in the kidney, renal inflammation, and fibrosis, thereby alleviating kidney damage in hyperuricemia mouse models without hepatoxicity. The results demonstrated that targeting liver Xor with GalNAc-siRNAs was a promising strategy for hyperuricemia therapy.

Schlagwörter

Stichwörter der Autor:innen

GalNAc-siRNAhyperuricemiaxanthine oxidoreductase

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Cell Biology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
  • Shanghai Synvida Biotechnology Co., Ltd., Shanghai 201203, China.

ORCID-Profile: Yingjie Xu

Förderung

  • National Natural Science Foundation of China
  • National Key R&D Program of China
  • Innovative Research Team of High-level Local Universities in Shanghai
  • Shanghai Rising-Star Program
  • National Key R&D Program of China

Zitieren

APA

Sun, H., Wang, X., Li, Y., Shen, Y., Zhang, L., Xu, Y., Liu, J., & Fan, X. (2024). Targeting Liver Xor by GalNAc-siRNA Is an Effective Strategy for Hyperuricemia Therapy. Pharmaceutics, 16(7), 938. https://doi.org/10.3390/pharmaceutics16070938

Vancouver

Sun H, Wang X, Li Y, Shen Y, Zhang L, Xu Y, et al. Targeting Liver Xor by GalNAc-siRNA Is an Effective Strategy for Hyperuricemia Therapy. Pharmaceutics. 2024;16(7):938. doi:10.3390/pharmaceutics16070938

BibTeX
@article{Sun2024,
  author = {Sun, Huiyan and Wang, Xinxia and Li, Yongqiang and Shen, Yingzhi and Zhang, Lin and Xu, Yingjie and Liu, Junling and Fan, Xuemei},
  title = {Targeting Liver Xor by GalNAc-siRNA Is an Effective Strategy for Hyperuricemia Therapy},
  journal = {Pharmaceutics},
  year = {2024},
  volume = {16},
  number = {7},
  pages = {938},
  doi = {10.3390/pharmaceutics16070938}
}
Kostenlos starten →